[go: up one dir, main page]

MX2017000083A - Compuestos de platino, composiciones y usos de estos. - Google Patents

Compuestos de platino, composiciones y usos de estos.

Info

Publication number
MX2017000083A
MX2017000083A MX2017000083A MX2017000083A MX2017000083A MX 2017000083 A MX2017000083 A MX 2017000083A MX 2017000083 A MX2017000083 A MX 2017000083A MX 2017000083 A MX2017000083 A MX 2017000083A MX 2017000083 A MX2017000083 A MX 2017000083A
Authority
MX
Mexico
Prior art keywords
compositions
platinum compounds
reacting
protein
antibody
Prior art date
Application number
MX2017000083A
Other languages
English (en)
Inventor
Mark T Bilodeau
Moreau Benoit
Meetze Kristan
Singh Sukhjeet
Wooster Richard
Whalen Kerry
Andre LEMELIN Charles-
Original Assignee
Placon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017000083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Placon Therapeutics Inc filed Critical Placon Therapeutics Inc
Publication of MX2017000083A publication Critical patent/MX2017000083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las presentes instrucciones se relacionan con compuestos y composiciones para el tratamiento de cánceres. En algunas modalidades, la composición comprende un complejo de platino (IV) que tiene al menos un grupo reactivo adecuado para la reacción con un grupo funcional en una proteína, proteína diseñada genéticamente, anticuerpo, fragmento de anticuerpo, péptido, agonista, antagonista, aptámero o ligando que puede ser capaz de reconocer una población de células objetivo seleccionada y/o derivados/análogos/miméticos de estos.
MX2017000083A 2014-06-23 2015-06-23 Compuestos de platino, composiciones y usos de estos. MX2017000083A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462015714P 2014-06-23 2014-06-23
US201462034124P 2014-08-06 2014-08-06
US201462035126P 2014-08-08 2014-08-08
US201462035739P 2014-08-11 2014-08-11
US201562150045P 2015-04-20 2015-04-20
PCT/US2015/037071 WO2015200250A1 (en) 2014-06-23 2015-06-23 Platinum compounds, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
MX2017000083A true MX2017000083A (es) 2017-05-30

Family

ID=54938720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000083A MX2017000083A (es) 2014-06-23 2015-06-23 Compuestos de platino, composiciones y usos de estos.

Country Status (14)

Country Link
US (3) US9403858B2 (es)
EP (2) EP3797768A1 (es)
JP (2) JP6336681B2 (es)
KR (1) KR101915452B1 (es)
CN (1) CN106659706B (es)
AU (2) AU2015280204B2 (es)
BR (1) BR112016030310A2 (es)
CA (1) CA2953350C (es)
IL (1) IL249646B (es)
MX (1) MX2017000083A (es)
NZ (1) NZ727701A (es)
SG (1) SG11201610656QA (es)
WO (1) WO2015200250A1 (es)
ZA (1) ZA201608543B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015102922A1 (en) * 2013-12-31 2015-07-09 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
WO2015200250A1 (en) * 2014-06-23 2015-12-30 Blend Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
WO2016209935A1 (en) * 2015-06-23 2016-12-29 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
US10342801B2 (en) 2015-06-23 2019-07-09 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
MX377528B (es) 2015-12-09 2025-03-10 Univ Wien Med Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
CN105622674B (zh) * 2016-02-29 2018-02-02 东南大学 一类含有生物活性基团的四价铂配合物及其制备方法
CN106046062B (zh) * 2016-07-01 2018-09-11 中国科学院上海药物研究所 两亲性奥沙利铂前体，其制备方法及用途
CN110950915B (zh) * 2019-12-24 2022-07-22 玉林师范学院 一种新型大黄酸类-铂(iv)前体抗癌配合物及其合成方法与应用
CN111205331B (zh) * 2020-02-24 2021-06-15 南京大学 一种具有抗耐药性功能的抗肿瘤四价铂配合物及制备方法
WO2022052014A1 (zh) * 2020-09-11 2022-03-17 上海海聚生物科技有限公司 一类治疗癌症用的铂类化合物及其制备方法
CN114539320B (zh) * 2020-11-25 2026-01-27 北京大学 辐射激活的四价铂配合物及其用途
US20230042086A1 (en) * 2021-07-23 2023-02-09 The Procter & Gamble Company Compositions for controlling arthropods
CN114249773B (zh) * 2021-12-06 2022-12-30 苏州大学 释放一氧化氮的四价铂类化合物及其制备和应用
CN114230616B (zh) * 2022-02-22 2022-04-29 江苏南创化学与生命健康研究院有限公司 一种癌细胞靶向的抗癌Pt配合物及其制备方法与应用
US11999924B2 (en) 2022-06-27 2024-06-04 The Procter & Gamble Company Stable aqueous surfactant compositions
CN117820080A (zh) * 2023-01-10 2024-04-05 陈学军 一种Reppe法改良式BDO生产工艺
CN116621900B (zh) * 2023-01-10 2024-05-07 河南大学 一种基于调控Mucin型O-糖基化靶向CRPC的四价铂氨基己糖配合物及其应用
US12171841B1 (en) 2024-07-19 2024-12-24 Imam Mohammad Ibn Saud Islamic University Synthesis and characterization of glauconite-based silicate nanorods as anticancer agent
US12427104B1 (en) 2025-04-01 2025-09-30 Ingenus Pharmaceuticals, Llc Injectable carboplatin formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550187A (en) 1984-04-12 1985-10-29 The Research Foundation Of State University Of New York Synthesis of platinum (IV) antineoplastic agents
US5041578A (en) 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE197249T1 (de) 1994-08-08 2000-11-15 Debiopharm Sa Stabiles arzneimittel enthaltend oxaliplatin
US20040220078A1 (en) 2001-03-02 2004-11-04 Houssam Ibrahim Device for packaging an oxaliplatinum solution
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
WO2006066595A2 (en) 2004-12-22 2006-06-29 Novozymes A/S Recombinant production of serum albumin
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
PE20142451A1 (es) 2012-02-27 2015-02-04 Amunix Operating Inc Composiciones de conjugados de xten y metodos para realizar las mismas
US20130252832A1 (en) 2012-03-22 2013-09-26 Yale University KRAS Variant and Tumor Biology
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
RU2657591C2 (ru) 2012-08-31 2018-06-14 ТАРИС Биомедикал ЛЛК Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
US20160166715A1 (en) 2013-07-30 2016-06-16 Tarveda Therapeutics, Inc. Nanoparticle Diagnostic and Methods for Treating Disease
CN105744983B (zh) 2013-08-12 2019-12-27 纳米医学系统公司 用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
WO2015102922A1 (en) * 2013-12-31 2015-07-09 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
WO2015200250A1 (en) * 2014-06-23 2015-12-30 Blend Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
WO2016209935A1 (en) * 2015-06-23 2016-12-29 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
MX377528B (es) * 2015-12-09 2025-03-10 Univ Wien Med Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.

Also Published As

Publication number Publication date
IL249646B (en) 2019-05-30
NZ727701A (en) 2018-04-27
US10322137B2 (en) 2019-06-18
CN106659706A (zh) 2017-05-10
US9403858B2 (en) 2016-08-02
JP2017522377A (ja) 2017-08-10
AU2015280204B2 (en) 2018-10-18
KR101915452B1 (ko) 2018-11-06
CA2953350A1 (en) 2015-12-30
US9937187B2 (en) 2018-04-10
KR20170021854A (ko) 2017-02-28
ZA201608543B (en) 2019-04-24
EP3157515B1 (en) 2021-05-26
EP3157515A1 (en) 2017-04-26
JP6336681B2 (ja) 2018-06-06
JP2018141000A (ja) 2018-09-13
WO2015200250A1 (en) 2015-12-30
CN106659706B (zh) 2020-03-20
US20160317549A1 (en) 2016-11-03
IL249646A0 (en) 2017-02-28
BR112016030310A2 (pt) 2017-08-22
EP3797768A1 (en) 2021-03-31
JP6659764B2 (ja) 2020-03-04
AU2015280204A1 (en) 2017-01-12
EP3157515A4 (en) 2018-01-03
CA2953350C (en) 2019-11-26
AU2018236864A1 (en) 2018-10-18
US20160068557A1 (en) 2016-03-10
SG11201610656QA (en) 2017-01-27
US20180008614A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
JOP20200016B1 (ar) أجسام مضادة لـ cd137
MX380778B (es) Compuestos y métodos para la modulación de expresion de proteína cinasa de distrofia miotónica (dmpk).
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
MD20150100A2 (ro) Virusurile bolii de Newcastle şi utilizarea acestora
UA114901C2 (uk) Інгібітори асс та їх застосування
PH12015502039B1 (en) Anti-lag-3 binding proteins
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
BR112017020054A2 (pt) anticorpos para icos
MX391989B (es) Conjugados de amatoxina y anticuerpos.
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MA38500A1 (fr) Systèmes et procédés pour analyser une nourriture pour animal
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
MX381278B (es) Composición para la estimulación ovárica controlada.
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
TW201613974A (en) Tumor-selective CTLA-4 antagonists
MY176200A (en) Binding polypeptides having a mutated scaffold
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
EA201791716A1 (ru) Фармацевтический состав
NZ731491A (en) Cd83 binding proteins and uses thereof